Greenwich LifeSciences, Inc. (GLSI): Cash & Equivalents
$6.18M
As of 2025-12-31
-22.9%
3-year compound annual growth
-26.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.18M | +51.0% | 2026-06-01, Balance as of period end |
| 2024-12-31 | $4.09M | -41.5% | 2026-06-01, Balance as of period end |
| 2023-12-31 | $6.99M | -48.1% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $13.47M | -50.5% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $27.20M | -5.1% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $28.66M | n/m | 2022-03-21, Balance as of period end |
| 2019-12-31 | $6.8K | n/a | 2021-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $6.18M | +51.0% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $3.09M | -44.0% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $4.98M | n/m |
| Kairos Pharma, Ltd. (KAPA) | 2025-12-31 | $4.49M | +253.1% |
| Ernexa Therapeutics Inc. (ERNA) | 2024-12-31 | $1.73M | -77.2% |
| Adial Pharmaceuticals, Inc. (ADIL) | 2025-12-31 | $5.88M | +56.8% |
| CDT Equity Inc. (CDT) | 2025-12-31 | $1.51M | +172.4% |
| AEON Biopharma, Inc. (AEON) | 2025-12-31 | $3.01M | n/m |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $3.06M | -16.8% |
Compare GLSI, GOVX, HIND, KAPA side by side · Screen every company in Pharmaceutical Preparations ↗